BUILDING SAFER AND MORE POTENT TREATMENTS FOR CANCER
OUR SOLUTION
Deliver precision medicines that act on the surface of diseased cells.
DISCOVERY
Cells construct unique protein complexes on their surfaces. The science of a cell’s Surfaceome is just beginning to be understood, but it is clear that this network of interacting proteins is critical to the growth of all cells.
Centrose discovered that on cancer cells, many proteins complex with the sodium-potassium ATPase or NKA. This essential protein is required because it maintains the cells’ membrane potential and nature provided a large class of drugs that modulate its functions.
This knowledge led Centrose to develop EDC Technology that targets and kills diseased cells by modulating the NKA only when it forms a complex with known cancer markers. Centrose went on to discover that EDC type therapies kill cancer by a process known as “necrosis”. Though a yet to be exploited death pathway for cancer, it has the potential to overcome drug resistance and turn cancers "hot", an important goal when treating patients with check-point inhibitors like Yervoy and Keytruda.
REPORTS
As we reported in our cell press publication, Centrose discovered that drug targets were interacting with cancer markers. Along with this came the idea that antibodies to these markers could be used to deliver drugs with exquisite precision using EDC Technology. EDC therapies inhibit growth and induce necrosis, thus offer a completely new and precise mechanism for treating cancer.
The Centrose PIPELINE
EDC9 targets B-Cells and will initially be tested on patients with drug resistant Non-Hodgkin's Lymphomas (NHL).
EDC1 kills metastatic cancers that express a protein called dysadherin, which allows cancer to spread throughout the body.
EDC8 targets CD38 which forms protein complexes on the surface of Acute Myeloid Leukemia (AML) cells.
